There is no commercial support for this activity.

About the speaker

Dr. Waxmonsky is the Division Chief of Child Adolescent Psychiatry at the Hershey Medical Center, the University Chair in Child Psychiatry at Penn State and a Professor of Psychiatry at the Penn State College of Medicine. His research focuses on the integration of medication and behavioral treatments targeting both children and their parents to improve the long-term efficacy and tolerability of ADHD treatments. He has a particular focus on the assessment and treatment of irritability in youth with ADHD and other behavioral disorders. He runs a clinical practice that provides assessment and treatment services for ADHD across the lifespan. He oversees the development and expansion of Pediatric Behavioral Health Integrated Care Programs at the Penn State Health and is the medical director of the Telephonic Psychiatry Services Program at Penn State Health that covers central and northeastern Pennsylvania.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

James G. Waxmonsky, MD, reports he is a researcher for Supernus and performs consulting work with Adlon Pharmaceuticals and Intracellular Therapies, Inc. He will discuss off-label pharmaceutical use in the treatment of irritability and aggression in generic terms. Review of his materials showed no conflicts of interest.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Todd Peters, MD, Deepak Prabhakar, MD, Briana Riemer, MD, Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PhD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Bruce Boxer, PhD, MBA, MA, MSN, RN, NPD-BC, NEA-BC, MCHES, CPHQ, Stacey Garnett, RN, MSN, Heather Billings, RN, and Jennifer Tornabene.